Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-24
2006-10-24
Campell, Bruce R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07125845
ABSTRACT:
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
REFERENCES:
patent: 6329379 (2001-12-01), Llinas-Brunet et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 2002/0037998 (2002-03-01), Llinas-Brunet et al.
patent: WO00/09543 (2000-02-01), None
patent: WO00/059929 (2000-10-01), None
patent: WO00/59929 (2000-10-01), None
patent: WO03/053349 (2001-12-01), None
patent: WO2004/072243 (2004-08-01), None
Weinstein B.: “Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Passage.” Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins, XX, XX, vol. 7, 1983, pp. 266-357, XP002032461.
M. Llinàs-Brunet, et al., “Peptide-Based Inhibitors of the Hepatitis C Virus Serine Protease,” Bioorganic & Medicinal Chemistry Letters 8 (1998), pp. 1713-1718.
Lu Zhi-Hui
Miao Zhenwei
Nakajima Suanne
Or Yat Sun
Sun Ying
Campell Bruce R.
Edwards angell Palmer & Dodge, LLP
Enanta Pharmaceuticals, Inc.
Heard Thomas S.
Hsi Jeffrey D.
LandOfFree
Aza-peptide macrocyclic hepatitis C serine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aza-peptide macrocyclic hepatitis C serine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aza-peptide macrocyclic hepatitis C serine protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3674739